Exploring Potential Proteomic Biomarkers for Prognosis of Infective Endocarditis through Profiled Autoantibodies by an Immunomics Protein Array Technique

Protein Biomarkers for Infective Endocarditis


  • Chang-Hua Chen Division of Infectious Diseases, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
  • Ying-Cheng Chen Division of Cardiovascular Surgery, Changhua Christian Hospital, Taiwan
  • Ching-Hui Huang Division of Cardiology, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan
  • Shu-Hui Wang Division of Critical Care Medicine, Changhua Christian Hospital, Changhua, Taiwan
  • Jen-Shiou Lin Department of Laboratory Medicine, Changhua Christian Hospital, Changhua, Taiwan
  • Shou-Chen Lo Department of Life Sciences, National Chung Hsing University, Taichung County, Taiwan
  • Chieh-Chen Huang Ph.D. Program in Translational Medicine, National Chung Hsing University, Taichung County, Taiwan




Infective endocarditis , protein array, prognostic biomarkers


Though infective endocarditis (IE) is a life-threatening cardiac infection with a high mortality rate, the effective diagnostic and prognostic biomarkers for IE are still lacking. The aim of this study was to explore the potential applicable proteomic biomarkers for IE through the Immunome™ Protein Array system. The system was employed to profile those autoantibodies in IE patients and control subjects. Our results showed that interleukin-1 alpha (IL1A), nucleolar protein 4 (NOL4), tudor and KH domain-containing protein (TDRKH), G antigen 2B/2C (GAGE2), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and X antigen family member 2 (XAGE2) are highly differentially-expressed among IE and non-IE control. Furthermore, bactericidal permeability-increasing protein (BPI), drebrin-like protein (DBNL), signal transducing adapter molecule 2 (STAM2), cyclin-dependent kinase 16 (CDK16), BAG family molecular chaperone regulator 4 (BAG4), and nuclear receptor-interacting protein 3 (NRIP3) are differentially-expressed among IE and healthy controls. On the other hand, those previously identified biomarkers for IE, including erythrocyte sedimentation rate, C-reactive protein, rheumatoid factor, procalcitonin, and N-terminal-pro-B-type natriuretic peptide demonstrated only minor significance. With scientific rationalities for those highly differentially-expressed proteins, they could serve as potential candidates for diagnostic biomarkers of IE for further analysis.


Beynon RP, Bahl VK, Prendergast BD. 2006. Infective endocarditis. BMJ 333:334-9.

Chen CH. 1997. Nosocomial Infective Endocarditis: Four Cases Report. J Infect Dis Soc ROC. 8:76-9.

Chen CH, Chang IL, Wang SH, et al. 2020. Potential Novel Proteomic Biomarkers for Diagnosis of Vertebral Osteomyelitis Identified Using an Immunomics Protein Array Technique: Two Cases Reports. Medicine (Baltimore) (revised).

Chen CH, Lo MC, Hwang K, et al. 2001. Infective endocarditis with neurologic complications: 10-year experience. J Microbiol Immunol Infect. 34:119-24.

Chen CH, Tsai CD, Wu SL, et al. 2001. A retrospective study of infective endocarditis at Changhua Christian Hospital during the years 1989-1999. J Intern Med Taiwan. 12:177-83.

Cornelissen CG, Frechen DA, et al. 2013. Inflammatory parameters and prediction of prognosis in infective endocarditis. BMC Infect Dis. 13:272.

Gu Z, Eils R, Schlesner M. 2016. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics (Oxford, England). 32:2847-9.

Habib G, Hoen B, Tornos PT, et al. 2009. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 30:2369-413.

Habib G, Lancellotti P, Antunes MJ, et al. 2015. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 36:3075-128.

Knudsen JB, Fuursted K, Petersen E, et al. 2009. Infective endocarditis: a continuous challenge. The recent experience of a European tertiary center. J Heart Valve Dis.18:386-94.

Kocazeybek B, Kucukoglu S, Oner YA. 2003. Procalcitonin and C-reactive protein in infective endocarditis: correlation with etiology and prognosis. Chemotherapy. 49:76-84.

Koscielny G, An P, Carvalho-Silva D, et al. 2017. Open Targets: a platform for therapeutic target identification and validation. Nucleic Acids Res. 45:D985-D94.

Lang RM, Bierig M, Devereux RB, et al. 2005. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 18:1440-63.

Li JS, Sexton DJ, Mick N, et al. 2000. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 30:633-8.

Liu N, Xing R, Yang C, et al. 2014. HIP-55/DBNL-dependent regulation of adrenergic receptor mediates the ERK1/2 proliferative pathway. Molecular bioSystems. 10:1932-9.

Nelson D, Goldstein JM, Boatright K, et al. 2001. pH-regulated secretion of a glyceraldehyde-3-phosphate dehydrogenase from Streptococcus gordonii FSS2: purification, characterization, and cloning of the gene encoding this enzyme. J Dent Res. 80:371-7.

Nishimura RA, Otto CM, Bonow RO, et al. 2014. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 63:2438-88.

Snipsoyr MG, Ludvigsen M, Petersen E, et al. 2016. A systematic review of biomarkers in the diagnosis of infective endocarditis. Int J Cardiol. 202:564-70.

Teles C, Smith A, Lang S. 2012. Antibiotic modulation of the plasminogen binding ability of viridans group streptococci. Antimicrob Agents Chemother. 56:458-63.

Thiene G, Basso C. 2006. Pathology and pathogenesis of infective endocarditis in native heart valves. Cardiovasc Pathol. 15, 256-263.

Ward Jr JH. 1965. Hierarchical grouping to optimize an objective function J Am Stat Assoc. 58:236-44.

Watkin RW, Harper LV, Vernallis AB, et al. 2007. Pro-inflammatory cytokines IL6, TNF-alpha, IL1beta, procalcitonin, lipopolysaccharide binding protein and C-reactive protein in infective endocarditis. J Infect. 55:220-5.

Wei XB, Chen F, Huang JL, et al. 2017. Novel Risk Biomarker for Infective Endocarditis Patients With Normal Left Ventricular Ejection Fraction—Monocyte to High-Density Lipoprotein Cholesterol Ratio. Circ J. 82, 283-288.

Yim G, Wang HH, Davies J. 2006. The truth about antibiotics. Int J Med Microbiol. 296:163-70.



How to Cite

Chen, C.-H., Chen, Y.-C. ., Huang , C.-H., Wang, . S.-H. ., Lin, J.-S. ., Lo, S.-C., & Huang, C.-C. (2020). Exploring Potential Proteomic Biomarkers for Prognosis of Infective Endocarditis through Profiled Autoantibodies by an Immunomics Protein Array Technique: Protein Biomarkers for Infective Endocarditis. The Heart Surgery Forum, 23(5), E555-E573. https://doi.org/10.1532/hsf.3017